Doctor Manu says Favipiravir may not be approved by the US pointed out that Thailand may have to stop using it as a main drug Paxlovid-molnupiravir is expected to be used as the main drug in the future.
November 22nd, Dr. Manoon Leechawengwong, a respiratory specialist Wichaiyut Hospital He posted on Facebook about the COVID-19 drug issue, saying: “This past week had both good news and bad news about COVID-19 medicines.
Let’s start with the bad news first. Results of a phase 3 trial of Avigan favipiravir in the United States, Mexico and Brazil compared the real drug to placebo. When given as early as 5 days after the onset of symptoms But in the news that the results of the study were disappointing, the Japanese pharmaceutical companies that own the license for this drug (see photo) believed that the drug would not be approved in the United States. We will have to wait for the research results to be published. If this news is true It’s time for Thailand to stop using favipiravir. It will continue to be the main drug in the treatment of COVID-19.
The good news is the results of a Phase III study of PAXLOVID Paxlovid, Pfizer. in many countries in North and South America, Europe, Africa and Asia. Compare the real drug to the placebo. When given as early as 5 days after the onset of symptoms Hospitalization was reduced by 89% and no deaths in the PAXLOVID group, compared to 10 (1.6%) in the placebo group. The drug is available for all strains of coronavirus. breed The side effects of the drug were mild compared to placebo. This drug acts by inhibiting the 3CL protease enzyme, preventing the virus from multiplying. Pfizer is now waiting for the FDA. USA approved for emergency use (see figure) taken by mouth twice daily every 12 hours for 5 days.
In terms of efficacy, PAXLOVID was more effective at reducing serious illness than molnupiravir. In the near future, both PAXLOVID and molnupiravir will be used as the primary treatment for COVID-19.”